



ASX ANNOUNCEMENT

11 April 2018

Further U.S. Patent Granted for Cynata Cymerus™ Technology

Melbourne, Australia; 11 April 2018: Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), is pleased to announce that the U.S. Patent and Trademark Office (USPTO) has granted a further patent covering aspects of Cynata's proprietary Cymerus™ platform.

The patent entitled "Methods and materials for hematoendothelial differentiation of human pluripotent stem cells under defined conditions" covers certain proprietary methods relating to the platform's ability to efficiently manufacture mesenchymal stem cells (MSCs) at scale for therapeutic use.

The patent is owned by the University of Wisconsin–Madison's Wisconsin Alumni Research Foundation (WARF) and is among the intellectual property licensed exclusively from WARF to Cynata. The granting of this patent follows the receipt of the Notice of Allowance from the USPTO (announced in December 2017) and the granting of Orphan Drug Designation for Cynata's lead product, CYP-001, by the US Food and Drug Administration (FDA), as announced in March 2018.

"We are delighted that the USPTO has granted this additional patent around our core Cymerus technology," said Dr Ross Macdonald, Cynata's Chief Executive Officer. "This further strengthens Cynata's comprehensive patent portfolio and supports our unique technology that enables the scalable manufacture of consistent, high-quality MSC therapeutic products to treat a range of prevalent and devastating diseases worldwide."

The inventors named on the patent are Dr Gene Uenishi and Professor Igor Slukvin. Professor Slukvin is a founder, advisor and major shareholder of Cynata.

The patent (U.S. patent no. 9,938,499) has an expiration date of around 24 January 2035.

Ends

CONTACTS: Dr Ross Macdonald, CEO, 0412 119343, ross.macdonald@cynata.com
Daniel Paproth, Australia Media Contact, 0421 858 982 , daniel.paproth@mcpartners.com.au
Laura Bagby, U.S. Media Contact, 312-448-8098, lbagby@6degreespr.com

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company developing therapies based on its proprietary Cymerus™ stem cell technology platform. Cymerus overcomes critical issues in the production of therapeutic mesenchymal stem cells (MSCs) by enabling the economical manufacture of commercial-scale MSCs, independent of multi-donor limitations. Cymerus' novel approach utilises induced pluripotent stem cells (iPSCs) derived from a single blood donation to generate mesenchymoangioblasts (MCAs), a precursor that is used to manufacture an unlimited number of therapeutic MSCs. Cynata's unique "off-the-shelf" Cymerus platform has the potential to create a new standard in the development and manufacture of stem cell therapeutics.